Subsequently, the anti-cancer effects of allosteric PTPN11 inhibitors have been widely assessed in pre-clinical models and are under evaluation in early-stage clinical trials for the treatment of cancer (reviewed in [50,51]). The gene discussed is PTPN11; the disease is cancer.